GEN Highlights

Fiercebiotech News

  • ALS researchers at Harvard uncover new biomarker and drug target by Arlene Weintraub (2019/01/18 18:59)
    A mutated form of the gene that makes a protein called TDP-43 has been implicated in the brain disorder amyotrophic lateral sclerosis (ALS). New research out of Harvard has revealed a connection between TDP-43 and another gene—a link that could yield new approaches to treating the disease.
  • FDA clears Verily’s prescription-only ECG smartwatch by Conor Hale (2019/01/18 18:45)
    Verily, the Alphabet research division formerly known as Google Life Sciences, has received a 510(k) clearance from the FDA for its own clinical study smartwatch, complete with an on-demand ECG. But as a prescription-only device, it’s far from a competitor to Apple’s publicly available smartwatch.
  • Telehealth provider Tyto Care pulls in a total of $33.5M in series C by Conor Hale (2019/01/18 15:56)
    Tyto Care, which makes telehealth equipment for at-home doctor’s exams, has raised an additional $9 million through an expansion of its 2018 series C round, bringing its total up to $33.5 million.
  • Abbott snaps up replacement mitral valve maker Cephea by Conor Hale (2019/01/18 14:55)
    Abbott has exercised a three-year-old option to purchase Cephea Valve Technologies, a San Jose, California-based developer of minimally invasive mitral heart valve replacements.
  • Celgene strikes Obsidian deal to boost CAR-T options  by Nick Paul (2019/01/18 13:25)
    Celgene is pushing ahead with its immuno-oncology dealmaking program while working toward its $74 billion takeout by Bristol-Myers Squibb. The big biotech ended the week by expanding its CAR-T toolkit via a deal with Obsidian Therapeutics and placing an $80 million bet on Kyn Therapeutics.
  • Former Insmed CMO Streck resurfaces at Alder by Phil Taylor (2019/01/18 12:29)
    A few days after leaving Insmed to take up an “employment opportunity on the West Coast,” Paul Streck has popped up at migraine specialist Alder BioPharmaceuticals.
  • Novartis allies with Oxford academics for big data R&D drive by Nick Paul (2019/01/18 07:57)
    Novartis has teamed up with the University of Oxford to use artificial intelligence to improve drug development. The collaboration will analyze MRI data from 35,000 multiple sclerosis patients and results from IL-17 inhibitor trials to better understand diseases important to Novartis’ prospects.
  • Chutes & Ladders—Exoduses continue at AstraZeneca by Conor Hale (2019/01/17 19:11)
    CMO Sean Bohen and I-O head David Berman are leaving AstraZeneca, while Roche's Omar Khwaja and Pearl Huang land at new biotechs. Those moves plus more hirings, firings and retirings throughout the industry.
  • Apple, J&J to put the Apple Watch’s ECG through large-scale clinical testing by Conor Hale (2019/01/17 16:57)
    Apple and Johnson & Johnson are teaming up on a multiyear research study to see if the latest Apple Watch can help catch and diagnose elderly people with atrial fibrillation earlier and faster than before.
  • Proteus launches its first digital cancer chemotherapy pill by Conor Hale (2019/01/17 15:47)
    Smart-pill maker Proteus Digital Health has launched an oral chemotherapy equipped with its ingestible sensor, which aims to help oncologists track treatment effectiveness and adherence in their cancer patients.

Google News:Health